Montagu completed the acquisition of HTL Biotechnology from Bridgepoint.

Montagu, a European private equity firm, completed the acquisition of HTL Biotechnology, an international, fast-growing biotech and industrial firm leading the development and production of innovative pharmaceutical grade biopolymers, from Bridgepoint, a British private equity investor. Financial terms were not disclosed. "We look forward to partnering with Montagu. Their extensive experience in the healthcare field, will allow us to accelerate our growth, continue to innovate, and realise our international ambitions," Yvon Bastard, HTL CEO.